DrugPatentWatch Database Preview

Drugs in Development Information for Afuresertib

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Afuresertib?

Afuresertib is an investigational drug.

There have been 10 clinical trials for Afuresertib. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1^st 2015.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Prostatic Neoplasms. The leading clinical trial sponsors are GlaxoSmithKline, Laekna Limited, and Novartis Pharmaceuticals.

There are fifty-seven US patents protecting this investigational drug and four hundred and eighty-one international patents.

Summary for Afuresertib

US Patents	57
International Patents	481
US Patent Applications	245
WIPO Patent Applications	139
Japanese Patent Applications	34
Clinical Trial Progress	Phase 1 (2015-08-01)
Vendors	30

Recent Clinical Trials for Afuresertib

Title	Sponsor	Phase
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer	Laekna LLC	Phase 1
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian	Laekna Limited	Phase 2
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC	Laekna Limited	Phase 1/Phase 2

See all Afuresertib clinical trials

Clinical Trial Summary for Afuresertib

Top disease conditions for Afuresertib

Top clinical trial sponsors for Afuresertib

See all Afuresertib clinical trials

US Patents for Afuresertib

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Afuresertib		Treatment of ophthalmic conditions by selectively removing senescent cells from the eye	Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)
Afuresertib		.beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof	Quadriga Biosciences, Inc. (Los Altos, CA)
Afuresertib		Controlled release dosage form	TRIASTEK, INC. (Nanjing, CN)
Afuresertib		Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population	UNITY BIOTECHNOLOGY, INC. (Brisbane, CA) BUCK INSTITUE FOR RESEARCH ON AGING (Novato, CA) MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (Rochester, MN)
Afuresertib		Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways	Asana BioSciences, LLC (Lawrenceville, NJ)
Afuresertib		Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof	ZHEJIANG UNIVERSITY (Zhejiang, CN) SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (Shanghai, CN)

International Patents for Afuresertib

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Afuresertib	Australia	AU2015211021	2034-01-28
Afuresertib	Australia	AU2020244600	2034-01-28
Afuresertib	Brazil	BR112016017564	2034-01-28
Afuresertib	Canada	CA2939121	2034-01-28
Afuresertib	Canada	CA3100140	2034-01-28
Afuresertib	China	CN106163557	2034-01-28